AIMS: The P2Y12 inhibitor prasugrel is a prodrug, which is activated after its initial hydrolysis partly by cytochrome P450 (CYP) 3A4. Grapefruit juice, a strong inactivator of intestinal CYP3A4, greatly reduces the activation and antiplatelet effects of clopidogrel. The aim of this study was to investigate the effects of grapefruit juice on prasugrel. METHODS: In a randomized crossover study, seven healthy volunteers ingested 200 ml of grapefruit juice or water three times daily for 4 days. On day 3, they ingested a single 10 mg dose of prasugrel with an additional 200 ml of grapefruit juice or water. Plasma concentrations of prasugrel metabolites and the antiplatelet effect were measured. RESULTS:Grapefruit juice increased the geometric mean area under the plasma concentration-time curve (AUC(0-∞)) of the primary, inactive metabolite of prasugrel to 164% of the control value (95% confidence interval 122-220%, P = 0.008), without a significant effect on its peak plasma concentration (C(max)). The C(max) and AUC(0-∞) of the secondary, active metabolite were decreased to 51% (95% confidence interval 32-84%, P = 0.017) and 74% of the control value (95% confidence interval 60-91%, P = 0.014) by grapefruit juice (P < 0.05). The average platelet inhibition, assessed with the VerifyNow® method at 0-24 h after prasugrel intake, was 5 percentage points (95% confidence interval 1-10 percentage points) lower in the grapefruit juice phase than in the water phase (P = 0.034). CONCLUSIONS:Grapefruit juice reduces the bioactivation of prasugrel, but this has only a limited effect on the antiplatelet effect of prasugrel.
RCT Entities:
AIMS: The P2Y12 inhibitor prasugrel is a prodrug, which is activated after its initial hydrolysis partly by cytochrome P450 (CYP) 3A4. Grapefruit juice, a strong inactivator of intestinal CYP3A4, greatly reduces the activation and antiplatelet effects of clopidogrel. The aim of this study was to investigate the effects of grapefruit juice on prasugrel. METHODS: In a randomized crossover study, seven healthy volunteers ingested 200 ml of grapefruit juice or water three times daily for 4 days. On day 3, they ingested a single 10 mg dose of prasugrel with an additional 200 ml of grapefruit juice or water. Plasma concentrations of prasugrel metabolites and the antiplatelet effect were measured. RESULTS:Grapefruit juice increased the geometric mean area under the plasma concentration-time curve (AUC(0-∞)) of the primary, inactive metabolite of prasugrel to 164% of the control value (95% confidence interval 122-220%, P = 0.008), without a significant effect on its peak plasma concentration (C(max)). The C(max) and AUC(0-∞) of the secondary, active metabolite were decreased to 51% (95% confidence interval 32-84%, P = 0.017) and 74% of the control value (95% confidence interval 60-91%, P = 0.014) by grapefruit juice (P < 0.05). The average platelet inhibition, assessed with the VerifyNow® method at 0-24 h after prasugrel intake, was 5 percentage points (95% confidence interval 1-10 percentage points) lower in the grapefruit juice phase than in the water phase (P = 0.034). CONCLUSIONS:Grapefruit juice reduces the bioactivation of prasugrel, but this has only a limited effect on the antiplatelet effect of prasugrel.
Authors: Jessica L Fayer Rehmel; James A Eckstein; Nagy A Farid; John B Heim; Steve C Kasper; Atsushi Kurihara; Steven A Wrighton; Barbara J Ring Journal: Drug Metab Dispos Date: 2006-01-13 Impact factor: 3.922
Authors: K S Lown; D G Bailey; R J Fontana; S K Janardan; C H Adair; L A Fortlage; M B Brown; W Guo; P B Watkins Journal: J Clin Invest Date: 1997-05-15 Impact factor: 14.808
Authors: Florian Läpple; Oliver von Richter; Martin F Fromm; Tanja Richter; Klaus P Thon; Hermann Wisser; Ernst-Ulrich Griese; Michel Eichelbaum; Kari T Kivistö Journal: Pharmacogenetics Date: 2003-09
Authors: Maria L Veronese; Lisa P Gillen; Joanne P Burke; Ellen P Dorval; Walter W Hauck; Ed Pequignot; Scott A Waldman; Howard E Greenberg Journal: J Clin Pharmacol Date: 2003-08 Impact factor: 3.126
Authors: Christian Schoergenhofer; Eva-Luise Hobl; Thomas Staudinger; Walter S Speidl; Gottfried Heinz; Jolanta Siller-Matula; Christian Zauner; Birgit Reiter; Jacek Kubica; Bernd Jilma Journal: Thromb Haemost Date: 2017-07-06 Impact factor: 5.249
Authors: Matti K Itkonen; Aleksi Tornio; Anne M Filppula; Mikko Neuvonen; Pertti J Neuvonen; Mikko Niemi; Janne T Backman Journal: Clin Pharmacol Ther Date: 2017-12-23 Impact factor: 6.875